Bactiguard launches line extensions to BIP Foley Catheter

Bactiguard is launching two line extensions to its BIP Foley Catheter; Female, adapted to the female anatomy and Tiemann, which facilitates catheterization of men. BIP Foley Catheter reduces the risk of catheter associated urinary tract infections, which are common when using indwelling catheters.

"The demand for our BIP Foley Catheter is steadily increasing, and we are happy that we are now able to offer two new line extensions that increase the options for patients with indwelling catheters. The new line extensions make us even more competitive”, says Nina Nilsson, SVP Sales and Marketing at Bactiguard.

BIP Foley Catheter Silicone Female has a shorter catheter length, which is suitable for women who have a shorter urethra than men. 

A catheter with the curved Tiemann tip can be used to ease the passage through the curved male urethra. This type of tip is the second most frequently used after the Nelaton tip, which Bactiguard already has in its portfolio. 

Catheter associated urinary tract infection, CAUTI, is the most frequent healthcare associated infection of which a large proportion is caused by indwelling urinary catheters. CAUTI can lead to serious complications that cause a great deal of suffering for the patient, higher mortality rate and increased healthcare costs. The BIP Foley catheters are shown to significantly reduce bacteriuria, symptomatic urinary tract infections and the use of antibiotics. 

For further information, please contact:
Nina Nilsson, SVP Sales and Marketing, Mobile: +46 70 214 87 49

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on www.bactiguard.com

Tags: